Doxazosin for benign prostatic hyperplasia in primary care

Clinical Therapeutics

Volumn 19, Issue 6, 1997, Pages 1269-1277

  Guthrie, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Alpha 1 adrenergic blocker; Benign prostatic hyperplasia; BPH; Doxazosin; Hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ALPHA ADRENERGIC RECEPTOR BLOCKING; DRUG CHOICE; DRUG SELECTIVITY; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MALE; PRIMARY MEDICAL CARE; PROSTATE HYPERTROPHY; REVIEW;

EID: 0031408937     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80004-5     Document Type: Review

References (23)

1. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol. 1995;29:7-12.
2. Gee WF, Holtgrewe HL, Albertsen PC, et al. Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol. 1995; 154:205-206.
3. Hill SJ, Lawrence SL, Lepor H. New use for alpha blockers: Benign prostatic hyperplasia. Am Fam Phys. 1994;49:1885-1888.
4. Fontenot C, Fawzy A, Baudier MM, et al. Current practice patterns among primary care physicians in management of BPH and prostate cancer screening. J Urol. 1996;155:708A. Abstract 1587.
5. Nickel JC, Fradet Y, Boake RC, and the PROSPECT Study Group. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J. 1996;155:1251-1259.
6. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
7. Calais de Silva F, Boyle P, Maisonneuve P, et al. Hypertension in men with symptoms of lower urinary tract dysfunction. J Urol. 1996;155:630A. Abstract 1275.
8. Kaplan SA, Santarosa RP, Te AE. The incidence of hypertension in a population of men with benign prostatic hyperplasia: Analysis based on the AUA symptom score and race. Eur Urol. 1996;30(Suppl 2):99. Abstract 332.
9. Cockett AT, Aso Y, Denis L, et al. Recommendations of the International Consensus Committee. In: Cockett ATK, Khoury S, Aso Y, et al, eds. Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Channel Islands: Scientific Communication International; 1995:625-640.
10. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Quick Reference Guide for Clinicians. Rockville, Maryland: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, February 1994. AHCPR Publication No. 94-0583.
11. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995;49:295-320.
12. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study. J Urol. 1995; 154:110-115.
13. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol. 1995;154: 105-109.
14. Lepor H, Kaplan SA, Klimberg I, et al, for the Multicenter Study Group. Doxazosin in benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. J Urol. 1997; 157:525-530.
15. Guthrie RM. Doxazosin for the treatment of patients with hypertension and symptoms of benign prostatic hyperplasia. Am J Hypertens. 1996;9:119. Abstract.
16. Jardin A, Kirby R, Christensen M, et al. Doxazosin is equally well tolerated by older and younger normotensive men. J Urol. 1995;153:273A. Abstract 179.
17. Kaplan SA, Meade-D'Alisera P, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology. 1995;46:512-517.
18. Kirby RS. Doxazosin in BPH: Effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology. 1995;46:182-186.
19. d'Ancona FC, Francisca EAE, Debruyne FMJ, de la Rosette JJMCH. High energy transurethral microwave thermotherapy (TUMT) in the treatment of patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): Results after 2-years follow-up. J Urol. 1997;157:98A. Abstract 379.
20. Mompo JA, Paya JJ, Prosper F. Transurethral microwave thermotherapy (TUMT): Long-term results with high and low energy level in patients with benign prostatic hyperplasia (BPH). J Urol. 1997; 157:433A. Abstract 1691.
21. Nakamura K, Baba S, Saito S, et al. Improvement of clinical response by high intensity focused ultrasound for benign prostatic hyperplasia using Sonablate200. J Urol. 1997;157:433A. Abstract 1692.
22. Oesterling JE, Arbor A, Issa MM, et al. Long-term results of a prospective, randomized clinical trial comparing TUNA® to TURP for the treatment of symptomatic BPH. J Urol. 1997;157:328A. Abstract 1282.
23. Smith P. Other non-medical therapies. In: Cockett ATK, Khoury S, Aso Y, et al, eds. Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Channel Islands: Scientific Communication International; 1995:573-614.